Abstracts tagged "autoantigens and rheumatoid arthritis (RA)"

Abstract Number: 2114 • 2016 ACR/ARHP Annual Meeting
Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity
Jacqueline Dekkers¹, Marije K. Verheul², Jeroen Stoop³, Bisheng Liu⁴, Peter A. van Veelen⁵, Martin Hegen⁶, Stephen Rapecki⁷, Tom WJ Huizinga², Leendert A. Trouw⁴ and René Toes⁴, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, ⁶Inflammation, Wyeth Pharmaceuticals, Cambridge, MA, ⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Autoantibodies are an important hallmark of Rheumatoid Arthritis (RA). Approximately 50% of RA patients harbor anti-carbamylated protein (CarP) antibodies. These autoantibodies target proteins that…
Abstract Number: 1930 • 2015 ACR/ARHP Annual Meeting
Identification of a Broadly Immunogenic Prevotella Copri T Cell Epitope in Patients with Rheumatoid Arthritis
Annalisa Pianta¹, Elise E. Drouin¹, Sheila Arvikar², Klemen Strle¹, Jameson T. Crowley¹, Qi Wang³, Catherine E. Costello³ and Allen C. Steere⁴, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁴Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Specific microorganisms in the gut microbiome may have a pathogenic role in rheumatoid arthritis (RA). Recently, Scher et al. showed that Prevotella copri, an…
Abstract Number: 983 • 2014 ACR/ARHP Annual Meeting
Identification of Annexin A2 As an Autoantigen in Rheumatoid Arthritis and in Lyme Arthritis
Annalisa Pianta¹, Elise E. Drouin², Sheila Arvikar³, Catherine E. Costello⁴ and Allen C. Steere⁵, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ⁴Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁵Medicine, Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose Disease-associated HLA-DR molecules are the greatest genetic risk factor for rheumatoid arthritis (RA) and for antibiotic-refractory Lyme arthritis (LA). We have developed a novel…
Abstract Number: 922 • 2013 ACR/ARHP Annual Meeting
Role Of B Cells and/Or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis
Lisa K. Peterson¹, Jeremy Sokolove², Paul Jedlicka³, Lauren J. Lahey⁴, William H. Robinson⁵ and Leonard L. Dragone⁶, ¹Pediatrics, National Jewish Health, Denver, CO, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Pathology, University of Colorado Denver, Aurora, CO, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Dept of Pediatrics, National Jewish Health, Denver, CO
Background/Purpose: RA is a systemic condition affecting approximately 1% of the general population leading to progressive arthritis and extra-articular manifestations (ExRA), including interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].